home  aisling capital  life sciences private equity toggle navigation developing treatments for food allergies using standardized pharmaceuticalgrade food allergens and characterized oral desensitization immunotherapy learn more about aimmune innovative medicines for the treatment of hormonallydriven cancers aisling congratulates the management teams of aragon and seragon on their recent acquisitions by johnson  johnson and genentech respectively learn morelearn more about aragon  seragon coolsculpting® more science less fat aisling congratulates the management team of zeltiq on its recent acquisition by allergan learn more about zeltiq largest provider of biopharmaceutical development and commercial outsourcing services learn more about quintiles dalvance™ for the treatment of acute bacterial skin and skin structure infections aisling congratulates the management team of durata on its recent acquisition by actavis learn more about durata diagnostics to accurately identify sepsis pathogens in hours instead of days learn more about t biosystems t biosystems aragon  seragon aisling capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products services and technologies meet our team a combined  years of experience in the healthcare industry learn more see our portfolio  billion in assets with a track record of investing and returning capital since  learn more latest news t biosystems receives ce mark for tbacteria™ panel enabling commercialization in europe july   lexington mass july   globe newswire  t biosystems inc nasdaqttoo an emerging leader in the development of innovative diagnostic products to improve patient health announced today that it has received a ce… read more menlo therapeutics raises m july   menlo park calif july   prnewswire  menlo therapeutics inc announced today that the company has raised m to advance development of serlopitant a novel nk receptor antagonist as a oncedaily oral treatment… read more paratek announces phase  study of oralonly dosing of omadacycline met all primary and secondary fda and ema efficacy endpoints in acute bacterial skin infections july   boston july   globe newswire  paratek pharmaceuticals inc nasdaqprtk announced today positive topline results from a pivotal phase  clinical study comparing its oncedaily oral investigational antibiotic omadacycline to twicedaily oral linezolid… read more more news team  aisling capital  life sciences private equity toggle navigation team aisling capital team aisling capital is led by a group of investment professionals with diverse backgrounds in industry science and finance the team’s complementary backgrounds give aisling capital unique perspective on the key players events and forces shaping the life science industry and allow the fund to identify investment opportunities in working with our portfolio companies the principals of aisling capital seek to provide the financing relationships and guidance needed to build highly successful companies steven a elms managing partner steven a elms mr elms joined aisling in july of  and currently serves as one of the managing partners previously he was a principal in the life sciences investment banking group of hq during his five years at hq mr elms was involved in over  financing and ma transactions helping clients raise in excess of  billion in capital prior to hq mr elms traded mortgagebacked securities at donaldson lufkin  jenrette his previous healthcare sector experience includes over two years as a pharmaceutical sales representative for marion laboratories and two years as a consultant for the wilkerson group mr elms currently serves as a director of adma biologics earlens and loxo oncology previously he served as a director of advion biosciences ambit biosciences archimica cooperatief avera pharmaceuticals bioenvision cenerx biopharma cidara therapeutics lensar nextwave pharmaceuticals novazyme pharmaceuticals pernix therapeutics scerene healthcare and tria beauty and was chairman of the board of adams respiratory therapeutics map pharmaceuticals and oculex pharmaceuticals mr elms received his mba from the kellogg graduate school of management at northwestern university and his ba in human biology from stanford university andrew schiff md managing partner andrew schiff md dr schiff joined aisling in september of  and currently serves as one of the managing partners prior to aisling capital dr schiff practiced internal medicine for six years at the new york presbyterian hospital where he maintains his position as a clinical assistant professor of medicine dr schiff currently serves as a director of armgo pharma powervision and zeltiq aesthetics and as a board observer of zavante therapeutics prior board service includes adams respiratory therapeutics agile therapeutics arginox pharmaceuticals barrier therapeutics bioenvision cardiokine cempra pharmaceuticals miramar labs myogen skinmedica sirion therapeutics transenterix and quintiles board observer he is a longtime supporter and board member of the visiting nurse service of new york dr schiff received his md from cornell university medical college his mba from columbia university and his bs with honors in neuroscience from brown university dov a goldstein md managing partner dov a goldstein md dr goldstein joined aisling in  and currently serves as one of the managing partners prior to joining aisling dr goldstein served as executive vice president and chief financial officer of vicuron pharmaceuticals for five years up until its acquisition by pfizer while at vicuron pharmaceuticals he raised over  million in an ipo pipe followon and block trade transactions he led the valuation and finance due diligence for the merger with biosearch italia nuovo mercato biomi the first us and italian publictopublic company merger he also ran the investor relations and press relations efforts for the company prior to vicuron dr goldstein was director of venture analysis at healthcare ventures he also completed an internship in the department of medicine at columbiapresbyterian hospital dr goldstein currently serves as a director of adma biologics cempra pharmaceuticals and esperion therapeutics previously he served as a director of durata therapeutics acquired by actavis loxo oncology also served as chief financial officer and topaz pharmaceuticals acquired by sanofi and on other private company boards dr goldstein received his md from yale school of medicine he received his mba from columbia business school and his bs with honors from stanford university dennis j purcell founder and senior advisor dennis j purcell mr purcell is the original founder of aisling capital llc and currently serves as a senior advisor to aisling previously he served as the senior managing partner prior to aisling capital mr purcell served as managing director of the life sciences investment banking group at chase hq formerly hambrecht  quist “hq” for over five years while at hq he was directly involved with over two hundred completed transactions and supervised over  billion of financing and advisory assignments in the pharmaceutical biotechnology and medical products industries during his tenure bioworld and other industry publications cited hq as the leading underwriter of life sciences securities prior to joining hq mr purcell was a managing director in the healthcare group at painewebber inc mr purcell is a frequent commentator on the industry and has been honored in the “biotech hall of fame” by genetic engineering news named to the biotechnology allstars list by forbes asap honored as one of the top  irishamerican businessmen and cited as one of the top  contributors to the biotechnology industry mr purcell has served as a director of aton pharma bridge pharmaceuticals cengent therapeutics dynova laboratories paratek pharmaceuticals valentis and xanodyne pharmaceuticals he has served as a member of the advisory council at harvard medical school the board of directors of the biotechnology industry association as well as the new york biotechnology association the irvington institute and on the board of lek consulting he currently sits on the board of real endpoints summus global inc life science leader magazine –editorial advisory board ny bio association and is a member of the university of delaware investment visiting committee member mr purcell received his mba from harvard university and his bs in accounting from the university of delaware eric aguiar md partner eric aguiar md dr aguiar joined aisling in  prior to joining aisling dr aguiar was a partner at thomas mcnerney and partners a  million health care focused venture capital and growth equity fund from  dr aguiar was a managing director of healthcare ventures a health care venture capital fund from  he currently sits on the boards of biohaven and invitae corporation his prior board seats have included amarin oriel therapeutics inc acquired by novartis ag virdante pharmaceuticals inc acquired by momenta pharmaceuticals cardiokine inc acquired by cornerstone therapeutics skinmedica inc acquired by allergan vaxinate inc metaphore and d pharmaceuticals acquired by johnson  johnson he was ceo of genovo inc acquired by targeted genetics a biopharmaceutical company that specialized in gene delivery and gene regulation he was also executive director of theratech inc acquired by watson pharmaceuticals he was a vice president and managing director of philadelphia ventures from  to  dr aguiar is a member of the board of overseers of the tufts school of medicine and a member of the council on foreign relations he received his medical degree with honors from harvard medical school he graduated with honors from cornell university as a college scholar he was also a luce fellow and is a chartered financial analyst aftab r kherani md partner aftab r kherani md dr kherani joined aisling in  and currently serves as a partner previously dr kherani was an engagement manager for two years at mckinsey  company where he was a member of the pharmaceutical medical product and private equity practices prior to mckinsey dr kherani was a chief resident in surgery at duke university medical center where he completed his residency in general surgery he also completed a twoyear postdoctoral research fellowship investigating treatments for heart failure and arrhythmia at columbia university college of physicians  surgeons while at columbia he additionally served as an organ procurement fellow as part of the cardiothoracic transplantation team of new york presbyterian hospital dr kherani currently serves as a director of spirox and transenterix and as a board observer at armgo pharma earlens loxo oncology syros pharmaceuticals and t biosystems dr kherani received his md from duke university school of medicine where he was a howard hughes medical institute research fellowship recipient he also received his bs in biology and ab in economics from duke both magna cum laude graduating phi beta kappa stacey d seltzer partner stacey d seltzer ms seltzer joined aisling in  and currently serves as a partner previously ms seltzer was at scheringplough where she held roles in business development marketing and sales most recently serving as the us scheringplough brand lead for zetia while in business development ms seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions ranging from inlicensing deals to broad development and commercialization alliances prior to scheringplough ms seltzer was the director of business development for akceli a biotechnology company developing cellbased microarrays ms seltzer began her career as a management consultant for mckinsey  company ms seltzer serves as a director of aimmune therapeutics miramar labs and promentis pharmaceuticals and as a board observer of prolacta bioscience previously she served as a board observer for agile therapeutics durata therapeutics acquired by actavis and zeltiq aesthetics she also acted as the aisling representative for its investment in precision dermatology acquired by valeant and was closely involved in aisling’s investments in cytos dermira and powervision ms seltzer received her mba from the wharton school at the university of pennsylvania where she was a palmer scholar she received her ms and bs from yale university awarded cum laude in molecular biophysics and biochemistry josh bilenker md operating partner josh bilenker md dr bilenker joined aisling in  and currently serves as an operating partner he is president and chief executive officer of loxo oncology an aisling capital iii portfolio company prior to aisling dr bilenker served as a medical officer in the office of oncology drug products at the us food and drug administration for two years while at the fda he conducted clinical reviews of indstage and licensed biologic oncology products prior to joining the fda dr bilenker trained at the university of pennsylvania in internal medicine and medical oncology earning board certification in these specialties dr bilenker currently serves as a director of loxo oncology and viewray previously he served as a director of lensar roka bioscience and t biosystems and as a board observer at aragon pharmaceuticals he is also a board member of the nccn foundation and of bioenterprise dr bilenker received his md from the johns hopkins school of medicine he received his ab from princeton awarded summa cum laude in english scott braunstein md operating partner scott braunstein md dr braunstein serves as an operating partner at aisling capital he is senior vice president strategy and corporate development at pacira pharmaceuticals dr braunstein spent  years as a healthcare analyst and portfolio manager at jp morgan asset management where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates he reviewed pharmaceutical company strategies business models and management teams and provided stock recommendations for the jp morgan asset equity group dr braunstein serves as a director of esperion therapeutics stat medical and the cornell alumni association for the college of agriculture and life sciences dr braunstein received his md from the albert einstein college of medicine and completed his residency in internal medicine at cornell universitynew york hospital he received his bs from cornell university ayman sabi operating partner ayman sabi mr sabi is an independent consultant serving as an operating partner at aisling capital he is the founder of sabi medical group bv and a seasoned entrepreneur with almost  years of fiscal strategic and operational leadership mr sabi founded and led sabi ventures and sabi trading and contracting inc which focused on international trade retail and real estate formerly mr sabi was ceo andor director of white house  black market inc acquired by chico’s inc in  roadhouse grill inc ipo  nasdaq new global llc shopping centers sold  and national retail group inc mr sabi has a bs from north carolina state university wonpyo yun analyst wonpyo yun mr yun joined aisling in july  and serves as an analyst previously mr yun was an analyst in the healthcare investment banking group at credit suisse in new york mr yun holds an ab in molecular biology awarded magna cum laude from princeton university where he also received a certificate in finance robert j wenzel chief financial officer robert j wenzel mr wenzel joined aisling in june  and has served as chief financial officer since april  having previously served as controller for nine years for  years prior to joining aisling he was vice president at lazard alternative investments “lazard” where he supervised the financial reporting of several domestic and offshore private equity funds prior to joining lazard mr wenzel began his career at eisner  lubin llp a midsize public accounting firm where he performed audits and prepared tax reports for a diverse clientele attaining the role of senior accountant mr wenzel received his bba in accounting from baruch college in  and holds his certified public accountant license in the state of new york he is also a member of the american institute of certified public accountants and the new york state society of certified public accountants hannah wieder controller hannah wieder ms wieder joined aisling in march  and serves as the controller prior to joining aisling she was an audit manager in the wealth  asset management practice at ernst  young where her focus was on private equity ms wieder also spent six years in the financial services group at cohnreznick a midsize public accounting firm where she attained the role of audit manager and directed the annual audits of various clients within the financial services industry including private equity funds funds of funds and management companies ms wieder received her ms in accountancy from the zicklin school of business at baruch college and received her bs in business management and finance awarded magna cum laude from brooklyn college she is a certified public accountant licensed in the state of new york and is a member of the american institute of certified public accountants and the new york state society of certified public accountants jan hoerrner director of investor relations and marketing jan hoerrner ms hoerrner joined aisling in october of  and serves as the director of investor relations and marketing at aisling capital in this role ms hoerrner manages relationships with over eighty limited partners and is a key contributor in aisling’s fundraising and marketing efforts previously ms hoerrner was with hq a leading underwriter and strategic advisor to the biotechnology industry during her five years at hq ms hoerrner was responsible for coordinating their healthcare conferences and also served as administrative manager for the new york office ms hoerrner received her bs in business administration from bryant university about  aisling capital  life sciences private equity toggle navigation about a differentiated approach to healthcare aisling capital is a leading investment firm that invests in products technologies and global businesses that advance health since  aisling capital has raised over  billion in committed capital across four funds aisling capital invests in both private and public companies utilizing a wide variety of investment structures the aisling capital team’s combination of clinical operational and financial experience allows the firm to identify execute and realize investments across the life sciences industry investment professionals with a combined  years of experience in the healthcare industry billion dollars raised in committed capital across  funds with a track record of investing and returning capital since  investments made to date across development stage and capital structure including both private and public companies our strategy aisling capital seeks to identify differentiated healthcare products services and technologies that address unmet medical needs our business is to provide promising companies with meaningful capital resources and to assist them in achieving their growth objectives we identify healthcare companies at a stage in their development where an infusion of capital and strategic assistance will significantly enhance the opportunities for success our investments aisling capital makes investment decisions driven by fundamental assessment of scientific regulatory financial and commercial risks given our investment team’s broad skillset we invest across the life sciences including seed and venture financings of developmentstage companies smallcap publicly traded equities structured debt and royalty deals and largecap leveraged buyouts of profitable companies our approach aisling capital takes an active approach to investing working closely with portfolio companies to help them become valuebuilding enterprises with multiple opportunities for exit our investment professionals collaborate with management teams and contribute expertise and experience to help determine and execute strategy identify and evaluate business opportunities and address financial issues jan hoerrner  aisling capital toggle navigation team aisling capital team aisling capital is led by a group of investment professionals with diverse backgrounds in industry science and finance the team’s complementary backgrounds give aisling capital unique perspective on the key players events and forces shaping the life science industry and allow the fund to identify investment opportunities in working with our portfolio companies the principals of aisling capital seek to provide the financing relationships and guidance needed to build highly successful companies steven a elms managing partner steven a elms mr elms joined aisling in july of  and currently serves as one of the managing partners previously he was a principal in the life sciences investment banking group of hq during his five years at hq mr elms was involved in over  financing and ma transactions helping clients raise in excess of  billion in capital prior to hq mr elms traded mortgagebacked securities at donaldson lufkin  jenrette his previous healthcare sector experience includes over two years as a pharmaceutical sales representative for marion laboratories and two years as a consultant for the wilkerson group mr elms currently serves as a director of adma biologics earlens and loxo oncology previously he served as a director of advion biosciences ambit biosciences archimica cooperatief avera pharmaceuticals bioenvision cenerx biopharma cidara therapeutics lensar nextwave pharmaceuticals novazyme pharmaceuticals pernix therapeutics scerene healthcare and tria beauty and was chairman of the board of adams respiratory therapeutics map pharmaceuticals and oculex pharmaceuticals mr elms received his mba from the kellogg graduate school of management at northwestern university and his ba in human biology from stanford university andrew schiff md managing partner andrew schiff md dr schiff joined aisling in september of  and currently serves as one of the managing partners prior to aisling capital dr schiff practiced internal medicine for six years at the new york presbyterian hospital where he maintains his position as a clinical assistant professor of medicine dr schiff currently serves as a director of armgo pharma powervision and zeltiq aesthetics and as a board observer of zavante therapeutics prior board service includes adams respiratory therapeutics agile therapeutics arginox pharmaceuticals barrier therapeutics bioenvision cardiokine cempra pharmaceuticals miramar labs myogen skinmedica sirion therapeutics transenterix and quintiles board observer he is a longtime supporter and board member of the visiting nurse service of new york dr schiff received his md from cornell university medical college his mba from columbia university and his bs with honors in neuroscience from brown university dov a goldstein md managing partner dov a goldstein md dr goldstein joined aisling in  and currently serves as one of the managing partners prior to joining aisling dr goldstein served as executive vice president and chief financial officer of vicuron pharmaceuticals for five years up until its acquisition by pfizer while at vicuron pharmaceuticals he raised over  million in an ipo pipe followon and block trade transactions he led the valuation and finance due diligence for the merger with biosearch italia nuovo mercato biomi the first us and italian publictopublic company merger he also ran the investor relations and press relations efforts for the company prior to vicuron dr goldstein was director of venture analysis at healthcare ventures he also completed an internship in the department of medicine at columbiapresbyterian hospital dr goldstein currently serves as a director of adma biologics cempra pharmaceuticals and esperion therapeutics previously he served as a director of durata therapeutics acquired by actavis loxo oncology also served as chief financial officer and topaz pharmaceuticals acquired by sanofi and on other private company boards dr goldstein received his md from yale school of medicine he received his mba from columbia business school and his bs with honors from stanford university dennis j purcell founder and senior advisor dennis j purcell mr purcell is the original founder of aisling capital llc and currently serves as a senior advisor to aisling previously he served as the senior managing partner prior to aisling capital mr purcell served as managing director of the life sciences investment banking group at chase hq formerly hambrecht  quist “hq” for over five years while at hq he was directly involved with over two hundred completed transactions and supervised over  billion of financing and advisory assignments in the pharmaceutical biotechnology and medical products industries during his tenure bioworld and other industry publications cited hq as the leading underwriter of life sciences securities prior to joining hq mr purcell was a managing director in the healthcare group at painewebber inc mr purcell is a frequent commentator on the industry and has been honored in the “biotech hall of fame” by genetic engineering news named to the biotechnology allstars list by forbes asap honored as one of the top  irishamerican businessmen and cited as one of the top  contributors to the biotechnology industry mr purcell has served as a director of aton pharma bridge pharmaceuticals cengent therapeutics dynova laboratories paratek pharmaceuticals valentis and xanodyne pharmaceuticals he has served as a member of the advisory council at harvard medical school the board of directors of the biotechnology industry association as well as the new york biotechnology association the irvington institute and on the board of lek consulting he currently sits on the board of real endpoints summus global inc life science leader magazine –editorial advisory board ny bio association and is a member of the university of delaware investment visiting committee member mr purcell received his mba from harvard university and his bs in accounting from the university of delaware eric aguiar md partner eric aguiar md dr aguiar joined aisling in  prior to joining aisling dr aguiar was a partner at thomas mcnerney and partners a  million health care focused venture capital and growth equity fund from  dr aguiar was a managing director of healthcare ventures a health care venture capital fund from  he currently sits on the boards of biohaven and invitae corporation his prior board seats have included amarin oriel therapeutics inc acquired by novartis ag virdante pharmaceuticals inc acquired by momenta pharmaceuticals cardiokine inc acquired by cornerstone therapeutics skinmedica inc acquired by allergan vaxinate inc metaphore and d pharmaceuticals acquired by johnson  johnson he was ceo of genovo inc acquired by targeted genetics a biopharmaceutical company that specialized in gene delivery and gene regulation he was also executive director of theratech inc acquired by watson pharmaceuticals he was a vice president and managing director of philadelphia ventures from  to  dr aguiar is a member of the board of overseers of the tufts school of medicine and a member of the council on foreign relations he received his medical degree with honors from harvard medical school he graduated with honors from cornell university as a college scholar he was also a luce fellow and is a chartered financial analyst aftab r kherani md partner aftab r kherani md dr kherani joined aisling in  and currently serves as a partner previously dr kherani was an engagement manager for two years at mckinsey  company where he was a member of the pharmaceutical medical product and private equity practices prior to mckinsey dr kherani was a chief resident in surgery at duke university medical center where he completed his residency in general surgery he also completed a twoyear postdoctoral research fellowship investigating treatments for heart failure and arrhythmia at columbia university college of physicians  surgeons while at columbia he additionally served as an organ procurement fellow as part of the cardiothoracic transplantation team of new york presbyterian hospital dr kherani currently serves as a director of spirox and transenterix and as a board observer at armgo pharma earlens loxo oncology syros pharmaceuticals and t biosystems dr kherani received his md from duke university school of medicine where he was a howard hughes medical institute research fellowship recipient he also received his bs in biology and ab in economics from duke both magna cum laude graduating phi beta kappa stacey d seltzer partner stacey d seltzer ms seltzer joined aisling in  and currently serves as a partner previously ms seltzer was at scheringplough where she held roles in business development marketing and sales most recently serving as the us scheringplough brand lead for zetia while in business development ms seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions ranging from inlicensing deals to broad development and commercialization alliances prior to scheringplough ms seltzer was the director of business development for akceli a biotechnology company developing cellbased microarrays ms seltzer began her career as a management consultant for mckinsey  company ms seltzer serves as a director of aimmune therapeutics miramar labs and promentis pharmaceuticals and as a board observer of prolacta bioscience previously she served as a board observer for agile therapeutics durata therapeutics acquired by actavis and zeltiq aesthetics she also acted as the aisling representative for its investment in precision dermatology acquired by valeant and was closely involved in aisling’s investments in cytos dermira and powervision ms seltzer received her mba from the wharton school at the university of pennsylvania where she was a palmer scholar she received her ms and bs from yale university awarded cum laude in molecular biophysics and biochemistry josh bilenker md operating partner josh bilenker md dr bilenker joined aisling in  and currently serves as an operating partner he is president and chief executive officer of loxo oncology an aisling capital iii portfolio company prior to aisling dr bilenker served as a medical officer in the office of oncology drug products at the us food and drug administration for two years while at the fda he conducted clinical reviews of indstage and licensed biologic oncology products prior to joining the fda dr bilenker trained at the university of pennsylvania in internal medicine and medical oncology earning board certification in these specialties dr bilenker currently serves as a director of loxo oncology and viewray previously he served as a director of lensar roka bioscience and t biosystems and as a board observer at aragon pharmaceuticals he is also a board member of the nccn foundation and of bioenterprise dr bilenker received his md from the johns hopkins school of medicine he received his ab from princeton awarded summa cum laude in english scott braunstein md operating partner scott braunstein md dr braunstein serves as an operating partner at aisling capital he is senior vice president strategy and corporate development at pacira pharmaceuticals dr braunstein spent  years as a healthcare analyst and portfolio manager at jp morgan asset management where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates he reviewed pharmaceutical company strategies business models and management teams and provided stock recommendations for the jp morgan asset equity group dr braunstein serves as a director of esperion therapeutics stat medical and the cornell alumni association for the college of agriculture and life sciences dr braunstein received his md from the albert einstein college of medicine and completed his residency in internal medicine at cornell universitynew york hospital he received his bs from cornell university ayman sabi operating partner ayman sabi mr sabi is an independent consultant serving as an operating partner at aisling capital he is the founder of sabi medical group bv and a seasoned entrepreneur with almost  years of fiscal strategic and operational leadership mr sabi founded and led sabi ventures and sabi trading and contracting inc which focused on international trade retail and real estate formerly mr sabi was ceo andor director of white house  black market inc acquired by chico’s inc in  roadhouse grill inc ipo  nasdaq new global llc shopping centers sold  and national retail group inc mr sabi has a bs from north carolina state university wonpyo yun analyst wonpyo yun mr yun joined aisling in july  and serves as an analyst previously mr yun was an analyst in the healthcare investment banking group at credit suisse in new york mr yun holds an ab in molecular biology awarded magna cum laude from princeton university where he also received a certificate in finance robert j wenzel chief financial officer robert j wenzel mr wenzel joined aisling in june  and has served as chief financial officer since april  having previously served as controller for nine years for  years prior to joining aisling he was vice president at lazard alternative investments “lazard” where he supervised the financial reporting of several domestic and offshore private equity funds prior to joining lazard mr wenzel began his career at eisner  lubin llp a midsize public accounting firm where he performed audits and prepared tax reports for a diverse clientele attaining the role of senior accountant mr wenzel received his bba in accounting from baruch college in  and holds his certified public accountant license in the state of new york he is also a member of the american institute of certified public accountants and the new york state society of certified public accountants hannah wieder controller hannah wieder ms wieder joined aisling in march  and serves as the controller prior to joining aisling she was an audit manager in the wealth  asset management practice at ernst  young where her focus was on private equity ms wieder also spent six years in the financial services group at cohnreznick a midsize public accounting firm where she attained the role of audit manager and directed the annual audits of various clients within the financial services industry including private equity funds funds of funds and management companies ms wieder received her ms in accountancy from the zicklin school of business at baruch college and received her bs in business management and finance awarded magna cum laude from brooklyn college she is a certified public accountant licensed in the state of new york and is a member of the american institute of certified public accountants and the new york state society of certified public accountants jan hoerrner director of investor relations and marketing jan hoerrner ms hoerrner joined aisling in october of  and serves as the director of investor relations and marketing at aisling capital in this role ms hoerrner manages relationships with over eighty limited partners and is a key contributor in aisling’s fundraising and marketing efforts previously ms hoerrner was with hq a leading underwriter and strategic advisor to the biotechnology industry during her five years at hq ms hoerrner was responsible for coordinating their healthcare conferences and also served as administrative manager for the new york office ms hoerrner received her bs in business administration from bryant university portfolio  aisling capital  life sciences private equity toggle navigation portfolio aisling capital invests in products technologies and businesses that advance health in addition to investing in companies developing pharmaceutical biotechnology and medical products aisling invests in businesses that provide drug development manufacturing and other important services to the healthcare industry portfolio companies allsector biopharma consumer diagnostics medical device services geographic area exus midatlantic midwest mountain new england south west coast status currenthistoric aclaris therapeutics inc nasdaqgs acrs specialty pharmaceutical company focusing on identifying developing and commercializing topical drugs to address various needs in dermatology year invested fundiv sectorbiopharma company statuspublic investment statuscurrent locationmalvern pa websiteaclaristxcom adams respiratory therapeutics inc specialty pharmaceutical company engaged in the development commercialization and marketing of overthecounter and prescription drugs for the treatment of respiratory disorders year invested fundi sectorconsumer company statusacquired investment statushistoric locationchester nj websiterbcom adma biologics inc nasdaqcmadma biopharmaceutical company that develops manufactures and intends to market plasmabased biologics for the treatment and prevention of infectious diseases year invested fundii sectorbiopharma company statuspublic investment statuscurrent locationramsey nj websiteadmabiologicscom advion inc provider of bioanalytical testing equipment to the pharmaceutical industry year invested fundi sectorservices company statusprivate investment statushistoric locationithaca ny websiteadvioncom agile therapeutics inc nasdaqgmagrx womens health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products year invested fundiii sectorbiopharma company statuspublic investment statuscurrent locationprinceton nj websiteagiletherapeuticscom aimmune therapeutics inc nasdaqgsaimt biopharmaceutical company developing desensitization treatments for food allergies year invested fundiii sectorbiopharma company statuspublic investment statuscurrent locationbrisbane ca websiteaimmunecom ajax health medical device platform building a diversified portfolio of emerging medical device companies year invested fundiv sectormedical device company statusprivate investment statuscurrent locationmenlo park ca websitena allos therapeutics inc biopharmaceutical company engaged in the development and commercialization of anticancer therapeutics year invested fundi sectorbiopharma company statusacquired investment statushistoric locationwestminster co websitesppirxcom ambit biosciences corporation biopharmaceutical company focused on the discovery development and commercialization of drugs to treat oncology autoimmune and inflammatory diseases year invested fundi sectorbiopharma company statusacquired investment statushistoric locationsan diego ca websiteambitbiocom aragon pharmaceuticals inc oncology drug development company focused on novel therapeutics for prostate and breast cancer year invested fundiii sectorbiopharma company statusacquired investment statushistoric locationnew brunswick nj websitejnjcom archimica cooperatief ua manufacturer of active pharmaceutical ingredients and late state intermediates for the pharmaceutical industry year invested fundii sectorservices company statusacquired investment statushistoric locationamsterdam netherlands websiteeuticalscom armgo pharma inc biopharmaceutical company dedicated to the discovery and development of novel smallmolecule therapeutics to treat debilitating cardiac muscular and neurological disorders year invested fundii sectorbiopharma company statusprivate investment statuscurrent locationtarrytown ny websitearmgocom ascendis pharma as nasdaqgsasnd endocrinefocused biopharmaceutical company developing longacting human growth hormone for the treatment of pediatric growth hormone deficiency year invested fundiv sectorbiopharma company statuspublic investment statuscurrent locationhellerup denmark websiteascendispharmacom aton pharma inc biotechnology company focused on the development of novel treatments for cancer year invested fundi sectorbiopharma company statusacquired investment statushistoric locationtarrytown ny websitemerckcom audentes therapeutics inc nasdaqgmbold biotechnology company developing gene therapybased treatments in several serious rare diseases year invested fundiv sectorbiopharma company statuspublic investment statuscurrent locationsan francisco ca websiteaudentestxcom auxilium pharmaceuticals inc nasdaqgsauxl specialty pharmaceutical company that develops and markets pharmaceutical products for urology and sexual health year invested fundi sectorbiopharma company statuspublic investment statushistoric locationchesterbrook pa websiteauxiliumcom avanza laboratories llc contract research organization that provides glp complaint drug development services for biotechnology and pharmaceutical firms and government agencies year invested fundii sectorservices company statusacquired investment statushistoric locationgaithersburg md websitesmithersavanzacom axcan pharma inc specialty pharmaceutical company focused on the treatment of gastrointestinal disorders year invested fundi sectorbiopharma company statusacquired investment statushistoric locationquebec canada websiteactaviscom barrier therapeutics inc specialty pharmaceutical company focused on development and commercialization of dermatology drugs year invested fundi sectorbiopharma company statusacquired investment statushistoric locationprinceton nj websitestiefelcom bioenvision inc biotechnology company focused on the development and commercialization of drugs to treat oncology and infectious disease year invested fundi sectorbiopharma company statusacquired investment statushistoric locationnew york ny websitegenzymecom biohaven pharmaceuticals ltd nysebhvn biopharmaceutical company developing treatments for orphan neurologic indications and other areas of large unmet medical needs year invested fundiv sectorbiopharma company statuspublic investment statuscurrent locationnew haven ct websitebiohavenpharmacom cardiokine inc biotechnology company developing drugs for the treatment and prevention of cardiovascular diseases year invested fundi sectorbiopharma company statusacquired investment statushistoric locationphiladelphia pa websitechiesiusacom catalent inc nysectlt provider of advanced delivery technologies and development solutions for drugs biologics and consumer health products year invested fundii sectorservices company statuspublic investment statushistoric locationsomerset nj websitecatalentcom cempra inc nasdaqgscemp drug discovery and development company focused on infectious diseases and the treatment of drugresistant bacteria year invested fundii sectorbiopharma company statuspublic investment statushistoric locationchapel hill nc websitecempracom chimerix inc nasdaqgmcmrx biopharmaceutical company dedicated to discovering developing and commercializing novel oral antivirals in areas of high unmet medical need year invested fundiii sectorbiopharma company statuspublic investment statuscurrent locationdurham nc websitechimerixcom cidara therapeutics inc nasdaqgmcdtx drug discovery and development company focused on devastating fungal infections that often complicate cancer and transplant treatments year invested fundii sectorbiopharma company statuspublic investment statuscurrent locationsan diego ca websitecidaracom clovis oncology inc nasdaqgsclvs biopharmaceutical company focused on acquiring developing and commercializing innovative anticancer agents year invested fundiii sectorbiopharma company statuspublic investment statushistoric locationboulder co websiteclovisoncologycom collagenex pharmaceuticals inc specialty pharmaceutical company that develops and markets proprietary medical therapies to the dermatology market year invested fundi sectorbiopharma company statusacquired investment statushistoric locationnewton pa websitegaldermacom colorescience inc cosmetics company that manufactures and sells mineralbased products year invested fundi sectorconsumer company statusacquired investment statushistoric locationcarlsbad ca websitecoloresciencecom cynapsus therapeutics inc nasdaqgmcyna specialty pharmaceutical company focused on the treatment of off episodes in parkinson’s disease year invested fundiii sectorbiopharma company statusacquired investment statushistoric locationtoronto canada websitecynapsusca cytos biotechnology ag swxcytn biopharmaceutical company focused on the development of targeted immunotherapies with a vlp bcell vaccines platform and ongoing preclinical development programs based on the platform year invested fundiii sectorbiopharma company statuspublic investment statushistoric locationschlieren switzerland websitecytoscom dermira inc nasdaqgsderm specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients year invested fundiii sectorbiopharma company statuspublic investment statushistoric locationredwood city ca websitedermiracom durata therapeutics inc pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions for physicians and providers to advance patient care in infectious disease and acute illnesses year invested fundiii sectorbiopharma company statusacquired investment statushistoric locationchicago il websiteduratatherapeuticscom earlens corporation medical device company committed to providing hearing impaired patients a hearing solution that is designed to change the current standard of care for sound performance year invested fundiii sectormedical device company statusprivate investment statuscurrent locationmenlo park ca websiteearlenscorpcom esperion therapeutics inc nasdaqgmespr drug discovery and development company focused on therapies that prevent treat and reverse cardiovascular and metabolic diseases year invested fundii sectorbiopharma company statuspublic investment statuscurrent locationann arbor mi websiteesperioncom fg limited antifungal drug discovery and development company focused on novel therapies to treat life threatening invasive fungal infections year invested fundiv sectorbiopharma company statusprivate investment statuscurrent locationmanchester uk websitefgcom global blood therapeutics inc nasdaqgsgbt biopharmaceutical company developing novel therapies to improve the lives of patients with serious bloodbased disorders year invested fundiv sectorbiopharma company statuspublic investment statuscurrent locationsouth san francisco ca websiteglobalbloodtxcom ibrutinib royalty anticancer drug targeting bcell malignancies year invested fundiii sectorbiopharma company statusprivate investment statushistoric locationna websiteimbruvicacom infinity pharmaceuticals inc nasdaqgsinfi biopharmaceutical company dedicated to discovering developing and delivering bestinclass medicines to patients with difficulttotreat diseases year invested fundiii sectorbiopharma company statuspublic investment statushistoric locationcambridge ma websiteinficom intercept pharmaceuticals inc nasdaqgsicpt biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing our proprietary bile acid chemistry year invested fundiii sectorbiopharma company statuspublic investment statushistoric locationnew york ny websiteinterceptpharmacom intersect ent inc nasdaqgmxent commercial stage drugdevice company committed to improving the quality of life for patients with ear nose and throat conditions year invested fundiii sectormedical device company statuspublic investment statuscurrent locationmenlo park ca websitepropelopenscom lensar inc leader in nextgeneration femtosecond laser technology for refractive cataract surgery year invested fundii sectormedical device company statusprivate investment statuscurrent locationorlando fl websitelensarcom lombard medical inc nasdaqgmevar medical technology company specializing in developing manufacturing and marketing endovascular stentgrafts that address significant unmet needs in the repair of aortic aneurysms year invested fundiii sectormedical device company statuspublic investment statushistoric locationoxfordshire uk websitelombardmedicalcom loxo oncology inc nasdaqgmloxo biotechnology company developing targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations year invested fundiii sectorbiopharma company statuspublic investment statuscurrent locationstamford ct websiteloxooncologycom map pharmaceuticals inc specialty pharmaceutical company developing new therapies based on proprietary drug particle and inhalation technologies year invested fundi sectorbiopharma company statusacquired investment statushistoric locationmountain view ca websiteallergancom mei pharma inc nasdaqcmmeip oncology company focused on the clinical development of novel therapies for cancer year invested fundiii sectorbiopharma company statuspublic investment statushistoric locationsan diego ca websitemeipharmacom menlo therapeutics inc biopharmaceutical company developing an oral therapy for the treatment of chronic pruritus associated with various conditions and chronic cough year invested fundiv sectorbiopharma company statusprivate investment statuscurrent locationmenlo park ca websitemenlotherapeuticscom miramar labs inc otcmrlb medical device company focused on developing products for dermatologic medical conditions year invested fundiii sectormedical device company statuspublic investment statuscurrent locationsunnyvale ca websitemiradrycom myogen inc biopharmaceutical company focused on the discovery development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders year invested fundi sectorbiopharma company statusacquired investment statushistoric locationwestminster co websitegileadcom nextwave pharmaceuticals inc specialty pharmaceutical company developing extended release otc and prescription products for children and adults year invested fundii sectorbiopharma company statusacquired investment statushistoric locationcupertino ca websitepfizercom novazyme pharmaceuticals inc biotechnology company focused on drugs to treat lysosomal storage diseases year invested fundi sectorbiopharma company statusacquired investment statushistoric locationprinceton nj websitegenzymecom oculex pharmaceuticals inc ophthalmic drug delivery company with platform technology to facilitate the treatment of major sightthreatening eye diseases and conditions year invested fundi sectormedical device company statusacquired investment statushistoric locationsunnyvale ca websiteallergancom paratek pharmaceuticals inc nasdaqgmprtk biopharmaceutical company engaged in the discovery development and commercialization of antibiotics to save lives and alleviate suffering year invested fundii sectorbiopharma company statuspublic investment statuscurrent locationboston ma websiteparatekpharmcom pernix therapeutics inc nasdaqgmptx specialty pharmaceutical company primarily focused on the sales marketing and development of branded pharmaceutical products year invested fundiii sectorbiopharma company statuspublic investment statuscurrent locationhouston tx websitepernixtxcom pharmaron inc provider of research and development services for pharmaceutical and biotechnological industries worldwide year invested fundii sectorservices company statusprivate investment statushistoric locationbeijing china websitepharmaroncom planet biopharmaceuticals inc developer and manufacturer of allergenic extracts and other products for the treatment and prevention of allergy year invested fundii sectorconsumer company statusacquired investment statushistoric locationliberty mo websiteareslifesciencescom powervision inc developer of a fluidcontrolled intraocular lens year invested fundiii sectormedical device company statusprivate investment statuscurrent locationbelmont ca websitepowevisionlenscom precision dermatology inc specialty pharmaceutical company developing manufacturing and marketing prescription and consumer dermatology products year invested fundiii sectorbiopharma company statusacquired investment statushistoric locationcumberland ri websitevaleantcom prolacta bioscience inc biopharmaceutical company developing and marketing human milkbased nutritional products for premature infants in the neonatal intensive care unit year invested fundiv sectorbiopharma company statusprivate investment statuscurrent locationcity of industry ca websiteprolactacom promentis pharmaceuticals inc biopharmaceutical company focused on the discovery and development of firstinclass therapies to treat central nervous system disorders of system xc year invested fundiv sectorbiopharma company statusprivate investment statuscurrent locationmilwaukee wi websitepromentispharmacom protagonist therapeutics inc nasdaqgm ptgx clinicalstage biopharmaceutical company focuses on discovering and developing peptidebased new chemical entities to address significant unmet medical needs in inflammatory bowel diseases year invested fundiv sectorbiopharma company statuspublic investment statuscurrent locationmilpitas ca websiteprotagonistinccom quintiles transnational holdings inc nyseq contract pharmaceutical research and sales organization year invested fundi sectorservices company statuspublic investment statushistoric locationdurham nc websitequintilescom roka bioscience inc nasdaqgmroka molecular diagnostics company focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens year invested fundiii sectordiagnostics company statuspublic investment statushistoric locationwarren nj websiterokabiocom seragon pharmaceuticals inc biopharmaceutical company focused on developing drugs for the treatment of estrogen receptor dependent breast cancer year invested fundiii sectorbiopharma company statusacquired investment statushistoric locationsan diego ca websitegenecom sirion therapeutics inc ophthalmicfocused biopharmaceutical company engaged in the discovery development and commercialization of products for the protection and preservation of eyesight year invested fundii sectorbiopharma company statusacquired investment statushistoric locationtampa fl websitena skinmedica inc specialty pharmaceutical company focused on development and commercialization of dermatology drugs and cosmeceuticals year invested fundi sectorconsumer company statusacquired investment statushistoric locationcarlsbad ca websiteskinmedicacom sorrento therapeutics inc nasdaqcmsrne biopharmaceutical company engaged in the discovery acquisition development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs year invested fundiii sectorbiopharma company statuspublic investment statushistoric locationsan diego ca websitesorrentotherapeuticscom spirox inc medical device company that is focused on developing minimally invasive technologies that improve the quality of life for patients with nasal obstruction year invested fundiii sectormedical device company statusacquired investment statushistoric locationmenlo park ca websitespiroxmedcom sunesis pharmaceuticals inc nasdaqcmsnss biopharmaceutical company developing oncology therapeutics for the treatment of solid and hematologic cancers year invested fundiv sectorbiopharma company statuspublic investment statuscurrent locationsan francisco ca websitesunesiscom synergy pharmaceuticals inc nasdaqgssgyp biopharmaceutical company focused on the development of novel therapies based on the natural human hormone uroguanylin to treat gastrointestinal gi diseases and disorders year invested fundiii sectorbiopharma company statuspublic investment statushistoric locationnew york ny websitesynergypharmacom syros pharmaceuticals inc nasdaqgssyrs life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases year invested fundiii sectorbiopharma company statuspublic investment statuscurrent locationwatertown ma websitesyroscom t biosystems inc nasdaqgmttoo in vitro diagnostics company that has developed a technology platform that offers a rapid sensitive and simple alternative to existing diagnostic methodologies year invested fundiii sectordiagnostics company statuspublic investment statuscurrent locationlexington ma websitetbiosystemscom topaz pharmaceuticals inc specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets year invested fundii sectorbiopharma company statusacquired investment statushistoric locationhorsham pa websitesanofius transenterix inc nysemkttrxc medical device company that is focused on the development and commercialization of manual and robotic assisted surgical systems for minimally invasive surgery year invested fundiii sectormedical device company statuspublic investment statuscurrent locationmorrisville nc websitetransenterixcom tria beauty inc medical device company developing and commercializing athome lightbased skincare products year invested fundii sectorconsumer company statusprivate investment statuscurrent locationdublin ca websitetriabeautycom verona pharma plc nasdaqgmvrna ukbased biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant medical unmet needs year invested fundiv sectorbiopharma company statuspublic investment statuscurrent locationlondon uk websiteveronapharmacom versartis inc nasdaqgsvsar endocrinefocused biopharmaceutical company developing novel longacting recombinant human growth hormone for growth hormone deficiency year invested fundiii sectorbiopharma company statuspublic investment statuscurrent locationredwood city ca websiteversartiscom viewray inc otcqb vray medical device company developing advanced radiation therapy technology for the treatment of cancer year invested fundii sectormedical device company statuspublic investment statuscurrent locationoakwood village oh websiteviewraycom vivus inc nasdaqgsvvus biopharmaceutical company developing innovative nextgeneration therapies to address unmet needs in obesity diabetes sleep apnea and sexual health year invested fundii sectorbiopharma company statuspublic investment statushistoric locationmountain view ca websitevivuscom zavante therapeutics inc biopharmaceutical company focused on novel products that address serious unmet medical needs in the hospital year invested fundiv sectorbiopharma company statusprivate investment statuscurrent locationsan diego websitezavantecom zeltiq aesthetics inc nasdaqgszltq medical technology company focused on developing and commercializing products utilizing a controlled cooling technology platform for noninvasive fat reduction year invested fundiii sectorconsumer company statusacquired investment statushistoric locationpleasanton ca websitecoolsculptingcom aisling capital iii lp  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors aisling capital iii lp check out list of companies and businesses related to aisling capital iii lp find out aisling capital iii lp address and contact details view other people related to aisling capital iii lp  coworkers colleagues companions etc address  seventh avenue th fl new york  ny companies related to aisling capital iii lp cikcompany namepositioncompany addresstransenterix inc owner  davis drive suite  morrisville agile therapeutics inc poor farm road princeton durata therapeutics inc owner  south wacker drive suite  chicago  aisling capital iii lp on the web persons related to aisling capital iii lp  transenterix incnamepositioncityjackson adammiamikherani md aftabmiamikherani aftabmorrisvilleaisling capital partners iii llcnew yorkaisling capital partners iii llcnew yorkaisling capital partners iii llcnew yorkaisling capital partners iii lpnew yorkaisling capital partners iii lpnew yorkaisling capital partners iii lpnew yorkbiffi andreamorrisvillejoshua j angeldirector seattlejoshua j angeldirector new yorkfernando anthonymorrisvillebarry j beildirector seattleandrea biffidirector trezzano rosakenneth blockchief financial officer valley streamchen chaomiamichen chaomiamifilipi charlesmiamifilipi charlesmiamifilipi md charlesmiamichao c chentaipeichao c chendirector miamimilne davidmiamimilne davidmorrisvillestewart b daviscoo  secretary miamistewart b daviscoo miamistewart b daviscoo miamidougherty dennismiamidennis doughertydirector durhamdennis doughertydirector durhamsteve elmschestersteve elmsnew yorksteve elmsnew yorksteve elmsnew yorkanthony c j fernandochief operating officer morrisvillecharles filipiomahacharles filipidirector miamicharles filipichief medical officer miamifrost gamma investment trustmiamifrost gamma investment trustmiamifrost gamma investment trustmiamifrost gamma investment trustmiamifrost gamma investments trustmiamifrost gamma investments trustmiamifrost gamma investments trustmiamifrost gamma investments trustmiamiphillip md et al frost owner miamiphillip md et al frost owner miamiphillip md et al frost owner miamiphillip md et al frostmiamikenneth heithoffdirector minneapoliskenneth heithoffdirector fisher islandjane ph d hsiaodirector jane ph d hsiaodirector miamijane ph d hsiaodirector miamijane ph d hsiaomiamijane ph d hsiaodirector miamiadam s jacksonmiamiadam s jacksoncfo miamiadam s jacksonchief financial officer miamimudit k jainportola valleymartin jamesmiamimartin jamesmiamimartin jamesmiamihsiao janemiamihsiao janemiamihsiao janemorrisvillehsiao phd janemiamispragens jeffreymiamispragens jeffreymiamislattery josephmorrisvillestephen katzchief executive officer seattlestephen katzchief executive officer valley streamwillam n kelleydirector willam n kelleydirector morrisvillewayne kevinmiamiwayne kevinmiamiaftab kheranidirector new yorkpaul a laviolettedirector natickpaul a laviolettedirector bostonjames joseph martinchief financial officer miamidavid bruce milnedirector bostondavid bruce milne owner bostonrichard muellermiamirichard muellerchief operating officer morrisvillelaviolette paulmiamilaviolette paulmorrisvillerichard c pfenniger jrdirector miamirichard c pfenniger jrdirector miamirichard c pfenniger jrdirector miamirichard c pfenniger jrdirector morrisvillerichard c pfenniger jrmiamirichard c pfenniger jrdirector miamifrost md phillipmiamitodd popepresident and ceo miamitodd popepresident and ceo morrisvilledennis j purcellnew yorkdennis j purcellnew yorkdennis j purcellnew yorkpfenniger jr richardmiamipfenniger jr richardmiamipfenniger jr richardmiamijr pfenniger richardmorrisvillemueller richardmiamisteven d rubindirector miamisteven d rubindirector miamisteven d rubinmiamisteven d rubindirector miamiandrew n schiffnew yorkandrew n schiffnew yorkdr drew schiffnew yorklawrence schoenbergdirector seattlejoseph p slatteryevp and cfo joseph p slatteryevp and cfo morrisvillespa sofar owner trezzano rosajeffrey g spragenspresident and ceo miamijeffrey g spragenspresident and ceo miamijeffrey g spragenspresident and ceo miamijeffrey g spragensceo miamijeffrey g spragenspresident and ceo miamijeffrey g spragenspresident and ceo miamirichard s stack owner portola valleywilliam n starling jrdirector pocatellowilliam n starling jrdirector portola valleywilliam n starling jrdirector portola valleystepstone group holdings llc owner new yorkstepstone group holdings llcnew yorkstepstone group lpsan diegostepstone pc gp llcnew yorkstepstone pc gp llcnew yorkstepstone pioneer capital buyout fund ii lpnew yorkstepstone pioneer capital buyout fund ii lpnew yorkstepstone pioneer capital ii lpnew yorkstepstone pioneer capital ii lp fifth ave th floorinvestments lllp stepstonesynnew yorkinvestments lllp stepstonesynnew yorkrubin stevenmiamirubin stevenmiamidavis stewartmiamisv life sciences fund iv gp lpbostonsv life sciences fund iv lpbostonsv life sciences fund iv strategic partners l pbostonsvlsf iv llc owner bostonsynergy life science partners l p owner portola valleysynergy venture partners llcportola valleypope toddmiamipope toddmorrisvilleunimed investment inctaipeikevin waynedirector miamikevin waynedirector miamikevin waynedirector miamikevin waynedirector miamijr starling williammorrisvillekelley williammorrisvillestarling jr williammiamipersons related to aisling capital iii lp  agile therapeutics incnamepositioncitylele abhijeetnew yorklele abhijeetnew yorklele abhijeetprincetonaisling capital partners iii llcnew yorkaisling capital partners iii llcnew yorkaisling capital partners iii llcnew yorkaisling capital partners iii lpnew yorkaisling capital partners iii lpnew yorkaisling capital partners iii lpnew yorkaltomari allawrencevillealtomari alprincetonaltomari alprincetonaltomari alprincetonalfred altomarichairman and chief executive o princetonalfred altomarichief executive officer princetonschiff andrewprincetonschiff andrewnew yorkcare capital iii llc owner princetoncare capital investments iii lpprincetoncare capital offshore investments iii lpprincetonscott m coiantechief financial officer princetonblackwell dariamahwahmiller deanwaynekantesaria devangwaynegarner elizabethprincetonsteve elmschestersteve elmsnew yorksteve elmsnew yorkseth hz fischerdirector san diegoelizabeth garnersr vp  chief medical officer princetongeoffrey gilmoregeneral counsel cranburykaren hongdirector princetonjohn w hubbarddirector princetonab investor owner new yorktursi jamesprincetonhubbard johnprincetontsang joyceprincetonhong karenprincetonhong karenprincetonhong karenprincetonmacfarlane katieprincetonabhijeet j leledirector west berlinabhijeet j leledirector princetonpellegrini lorenzoprincetonpellegrini lorenzoprincetonkatie macfarlanechief commercial officer princetonwilliam mckeedirector woodcliff lakewilliam mckeeprincetonjay moorin owner suite jay moorin owner naplesschmitt paulwayneproquest associates iii llcprincetonproquest associates iii llcnaplesproquest associates iv llcprincetonproquest associates iv llcnaplesproquest investments iii lpprincetonproquest investments iii lpnaplesproquest investments iv lpprincetonproquest investments iv lpnaplesdennis j purcellnew yorkdennis j purcellnew yorkdennis j purcellnew yorkayres russellpittsburghandrew n schiffdirector new yorkandrew n schiffdirector new yorkandrew n schiffnew yorkdr drew schiffdirector new yorkalain schreiberprincetonalain schreibernaplescoiante scottprincetoncoiante scottprincetoncoiante scottprincetonrenee selmanchief commercial officer princetonajit shettydirector princetonrossi thomasprincetonjames patrick tursidirector malvernjames patrick tursidirector princetonmckee williamprincetonpersons related to aisling capital iii lp  durata therapeutics incnamepositioncitybrenton karl ahrensdirector westportbrenton karl ahrensdirector westportaisling capital partners iii llcnew yorkaisling capital partners iii llcnew yorkaisling capital partners iii lpnew yorkaisling capital partners iii lpnew yorksrinivas akkarajumenlo parksrinivas akkarajumenlo parksusan roberta allenmorristownangela gurski birchlermorristownjames c blair owner princetoneric buatoismenlo parkcanaan management incwestportcanaan management incwestportcanaan partners viii llcwestportcanaan partners viii llcwestportcanaan viii lpdirector westportcanaan viii lpdirector westportj martin carrolldirector chicagoj martin carrolldirector chicagophilippe o chambonnew yorkphilippe o chambonnew yorkphilippe o chambonnew yorkschutter richard u dedirector chicagoschutter richard u demorristownschutter richard u dedirector chicagoschutter richard u dedirector chicagojeani delagardellemenlo parkjeani delagardellemenlo parkjeani delagardellenew yorkassociates domain owner princetondomain partners viii lp owner princetonbrian h dovey owner princetondp viii associates lp owner princetonmichael w dunnechief medical officer morristownmichael w dunnechief medical officer chicagomichael w dunnechief medical officer chicagopaul r edickchief executive officer morristownpaul r edickchief executive officer chicagopaul r edickchief executive officer chicagosteve elmsnew yorksteve elmsnew yorkcorey n fishmancoo  cfo morristowncorey n fishmancfo  coo chicagocorey n fishmancfocoo chicagopaul a friedmandirector chicagopaul a friedmandirector chicagolisa m gilesdirector chicagolisa m gileschicagolisa m gilesdirector chicagodov a md goldsteindirector new yorkbrian k halak owner princetonjames healydirector menlo parkjames healymenlo parkgeorge f horner iiidirector morristownronald huntnew yorkronald huntdirector new yorkronald huntnew yorkkim p kamdarprincetonmilan kovacevicmorristownjeremy david lackmorristownvijay k lathimenlo parkvijay k lathimenlo parkvijay k lathinew yorknew leaf venture associates ii lpnew yorknew leaf venture associates ii lpnew yorknew leaf venture associates ii lpnew yorknew leaf venture management ii llcnew yorknew leaf venture management ii llcnew yorknew leaf venture management ii llcnew yorknew leaf ventures ii lpnew yorknew leaf ventures ii lp owner new yorkjames niedelnew yorkjames niedelnew yorkkevin c oboyledirector chicagokevin c oboyledirector chicagokevin c oboylemorristownbenjamin manlaui pemorristownbenjamin manlavi pechicagomichael powellmenlo parkdennis j purcellnew yorkdennis j purcellnew yorkliam ratcliffenew yorkandrew n schiffnew yorkandrew n schiffnew yorkkathleen k schoemaker owner princetonjohn patrick shannon jrmorristownjohn patrick shannon jrchief commercial officer chicagojohn patrick shannon jrchief commercial officer chicagosofinnova management vii llcmenlo parksofinnova venture partners vii l pmenlo parkgeorge harrison talbotmorristownjesse i treu owner princetonronald irving trustmorristownronald irving trustchicagonicole vitullodirector princetonwendy l yarnochicagowendy l yarnodirector chicago potentially same personnamecitycountryaisling capital iii lpnew yorknyaisling capital iii lpnew yorknyaisling capital iii lpnew yorknyaisling capital iii lpnew yorknyaisling capital iii lpnew yorkny bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version ﻿ insider aisling capital iii lp purchased  million of loxo oncology inc nasdaqloxo – octafinance tuesday  july  menu featured news  years ago  alphabet inc nasdaqgoogl tests its ad technology on billboards to cushion itself against ad blocks  years ago  china margin debt hits week high japan pumps’n’dumps as kyle bass fears looming em banking crisis  years ago  marc faber shares his insight in one hour exclusive interview he covers all from commodities and china to inflation the euro and gold  years ago  carl icahn criticizes the fed feels bad for investors buying junk bonds  years ago  john burbank european qe can’t save the markets same as the us quantitative easing everything will be liquidated insider aisling capital iii lp purchased  million of loxo oncology inc nasdaqloxo  by octastaff in insider buys m insider buys  owner insider news share with your friendsyour nameyour emailrecipient emailenter a messagei read this article and found it very interesting thought it might be interesting for you the article is called insider aisling capital iii lp purchased  million of loxo oncology inc nasdaqloxo and is was published by octafinancecom at httpwwwoctafinancecominsideraislingcapitaliiilppurchasedmillionofloxooncologyincnasdaqloxocaptchasubmit aisling capital iii lp insider buy transaction aisling capital iii lp known as an insider in loxo oncology inc nasdaqloxo    acquired  shares whose value is estimated to be  million at average stock price of  being a significant transaction it will probably not go ignored aisling capital iii lp presently has rights to   of loxo oncology inc’s market cap with ownership of  million shares  dated  the transaction filing is free at your disposal here loxo oncology inc stock rating sentiment and fundamentals aisling capital iii lp’s investment could mean only one that it’s confident when it comes to loxo oncology inc’s prospects and its stock price according to four leading equity analysts that are covering this firm’s earnings potential there is an expectation of per share earnings of  for the  year which gives loxo oncology inc a price to earnings ratio of nan rating  sentimentpsychsignal socialsellanalysts ratingbuyhedge funds sentimentbuy stock fundamentalsearnings  fcf trendsellsectorindustry macrobullishvaluation models technical analysisst trendupmt trenduplt trendup octafinance ratingbuy  read how our stock ratings system works we rate loxo oncology inc’s stock as buy not only because of the insider transaction by aisling capital iii lp but also in accordance with octafinance’s sophisticated equities time momentum model as shown below in the last  days the loxo oncology inc’s share price has seen a fast increase of   and is now in a very smooth bullish uptrend price chart of loxo oncology nasdaqloxo stock source rightedgesystems yahoo split  dividend adjusted data and octafinance interpretations based on our analysis and trend model aisling capital iii lp’s shareholders equity should advance by a total of  million usd should the stock price reaches our trading model target of  please share with us if you buy the stock of loxo oncology inc by commenting below hedge funds ownership latest f sec filings show  investment managers own shares in loxo oncology inc the institutional ownership of the company in the last quarter is low at   of the shares outstanding they increased by  million the total shares they hold as of that quarter these funds owned  million shares a total of  funds opened new positions in loxo oncology inc and  increased their holdings there were  funds that closed their positions and  that reduced them as revealed by sec’s f filings this company is in top  stock holdings of two hf some of these are aisling capital llc bvf inc il dennis purcell’s aisling capital llc is the most positive institutional investor on loxo oncology inc with ownership of  million shares as of q  for  of the fund’s portfolio bvf inc il is another positive institutional manager owning  million shares of the company or  of their stocks portfolio the stock is also  of the fund’s aum nea management company llc have  of their stock portfolio invested in the company for  million shares in addition james e flynn’s deerfield management co disclosed it had purchased a stake worth  of the fund’s stock portfolio in the company the new yorkbased fund orbimed advisors llc was also a notable believer in the listed company with ownership of  million shares loxo oncology inc is  of the fund’s stock portfolio loxo oncology nasdaqloxo company profile loxo oncology inc is engaged in discovery development and commercialization of targeted cancer therapies loxo is the company’s lead product and has completed its preclinical research loxo is an oral selective inhibitor of the tropomyosin receptor kinase trk family the company is developing it for the treatment of tumors with trk alterations trk has been implicated in various tumor types such as lung cancer head and neck cancer melanoma colorectal cancer sarcoma and breast cancer the company is conducting phase  clinical trial of loxo which is an open label multicenter trial and has two stages dose escalation and expansion the objectives of the dose escalation stage are to determine the tolerated dose and the appropriate dose for further clinical investigation as well as to determine the tolerability and pharmacokinetic profile of orally administered loxo company website loxo oncology currently its market worth is  million and it has  million outstanding shares as of writing there are  shareholders and the institutional ownership is  the firm has  employees loxo oncology inc was created in delaware on  the stock closed at  yesterday and it had average  days volume of  shares it is up from the  days average shares volume of  loxo oncology inc has a one year low of  and a  days high of  the stock price is above the  days sma loxo oncology inc last issued its quarterly earnings information on  the company reported  eps for the quarter missing the consensus estimate of  by  the company had a revenue of for  and for  therefore the revenue was down aisling capital iii lp is also director of agile therapeutics inc  percent owner of versartis inc t biosystems inc durata therapeutics inc transenterix inc zeltiq aesthetics inc  the securities are directly held by aisling capital iii – lp “aisling” – and indirectly held by aisling capital partners iii – lp “aisling gp” – as general partner of aisling – aisling capital partners iii llc “aisling partners” – as general partner of aisling gp – and each of the individual managing members and partners collectively – the “managers” of aisling gp and aisling partners the managers of aisling partners are dennis purcell – dr andrew schiff and steve elms mr elms is a member of the issuer’s board of directors dr joshua bilenker – the issuer’s president and chief executive officer – is a member of the issuer’s board of directors and an operating partner of aisling gp mr elms is a member of the investment committee the “investment committee” of aisling gp the investment committee has voting and dispositive power over the shares held by aisling loxo oncology  receive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with marketbeatcoms free daily email newsletter tagged aisling capital iii lploxo oncology  nasdaqloxo the director of patrick industries inc nasdaqpatk scott welch picked up  shares marubeni corp fi insider in aircastle limited nyseayr paid for  shares of the company loxo oncology  get news  ratings daily enter your email address below to get the latest news and analysts ratings for loxo oncology with our free daily email newsletter hedge fund newstop  citadel advisors f holdings in q df dent  co inc just released its q  stock positionsmaverick capital top  holdings in q analyzing ken griffins citadel advisors stock holdings in q lone pine capital top  f positions in q guru newsfelix zulauf sees a stock market correction coming this rally sp  indexspinx will be shortlivedmarc faber shares his insight in one hour exclusive interview he covers all from commodities and china to inflation the euro and goldjim grant the next thing might be helicopter money what to buy and where he sees investment opportunitieskyle bass bearish on emerging markets for at least  more years looking to short currenciesdavid tepper gets defensive is it time to get out of the stock market macro newschina margin debt hits week high japan pumps’n’dumps as kyle bass fears looming em banking crisisare us – russian relations a zerosum gameus and russia have launched direct talks on the conflict in syriayuan drops as pboc cuts reference rate by most since devaluationcould the market crash like —put volume spike argues low is nearctas newsred rock just published report about the trend following landscape  how ctas’ performance must be analyzedhow to implement dual momentum for nonus investorsdo commodity trading advisors ctas really provide crisis alpha equity hedge and are long volatility bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version   insider trading  aisling capital iii lp  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  aisling capital iii lp select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm syros pharmaceuticals inc syrs aisling capital iii lpaisling capital partners iii lpaisling capital partners iii llcelms steveschiff andrew npurcell dennis j owner    direct view purchase  pm loxo oncology inc loxo aisling capital iii lpaisling capital partners iii lpaisling capital partners iii llcelms steveschiff andrew npurcell dennis j owner    direct view purchase  pm loxo oncology inc loxo aisling capital iii lpaisling capital partners iii lpaisling capital partners iii llcelms steveschiff andrew npurcell dennis j owner    direct view purchase  pm t biosystems inc ttoo aisling capital iii lpaisling capital partners iii lpaisling capital partners iii llcelms steveschiff andrew npurcell dennis j owner    indirect view purchase  pm loxo oncology inc loxo aisling capital iii lpaisling capital partners iii lpaisling capital partners iii llcelms steveschiff andrew npurcell dennis j owner    direct view purchase  pm loxo oncology inc loxo aisling capital iii lpaisling capital partners iii lpaisling capital partners iii llcelms steveschiff andrew npurcell dennis j owner    direct view purchase  pm versartis inc vsar aisling capital iii lpaisling capital partners iii llcaisling capital partners iii lpelms stevepurcell dennis jschiff andrew n owner    indirect view purchase  pm agile therapeutics inc agrx aisling capital iii lpaisling capital partners iii llcaisling capital partners iii lpelms stevepurcell dennis jschiff andrew ndirector owner    indirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing conversion  pm nana syros pharmaceuticals inc syrs aisling capital iii lpaisling capital partners iii lpaisling capital partners iii llcelms steveschiff andrew npurcell dennis j owner   direct view conversion  pm nana syros pharmaceuticals inc syrs aisling capital iii lpaisling capital partners iii lpaisling capital partners iii llcelms steveschiff andrew npurcell dennis j owner   direct view other  pm nana agile therapeutics inc agrx aisling capital iii lpaisling capital partners iii llcaisling capital partners iii lpelms stevepurcell dennis jschiff andrew n owner   indirect view   secformcom all rights reserved archives        tue  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  aisling capital llc  law search advanced search take a free trial  sign in close law indepth law uk adv search  platform tools browse all sections banking bankruptcy class action competition employment energy expert analysis insurance intellectual property product liability securities rankings laws mvps glass ceiling report global  law  diversity snapshot practice group partner rankings practice groups of the year pro bono firms of the year rising stars trial aces site menu join the law team search legal jobs learn more about law read testimonials contact law sign up for our newsletters site map help aisling capital llc news  case alert on aisling capital llc financial » asset management » aisling capital llc menu options for aisling capital llc everything » news  analysis » new cases » new ptab cases » new ttab cases » case activity » outside counsel » data on cases clients outside counsel and individual attorneys collected from active federal civil cases reflects only recently published court data not intended to be exhaustive not responsible for errors in court dockets × please assign a name to this alert save alert cancel news  january   sec fines pershing square others for paytoplay violations  they were adams capital management aisling capital alta communications commonwealth venture january   fenwick guides cancer biotech loxos m followon  loxos largest shareholder is an affiliate of aisling capital an investment firm focused on the life july    ipos targeting b ready to rock st week of august  including longitude venture partners ii lp aisling capital iii lp and foresite capital fund ii lp an cases  no results ptab cases  no results ttab cases  no results to view all the results and drill down deeper take a free trial now try law free for seven days already a subscriber click here to login × already have access click here to login get instant access to the onestop news source for business lawyers register now get instant access to the onestop news source for business lawyers email professional email required first name last name please note a verification email will be sent to your address before you can access your trial password at least  characters required confirm password select at least one primary interest aerospace  defense appellate asset management automotive banking bankruptcy california capital markets class action commercial contracts competition consumer protection corporate cybersecurity  privacy delaware employment energy environmental financial services uk florida food  beverage government contracts health hospitality illinois immigration insurance insurance uk intellectual property international arbitration international trade law in depth legal ethics life sciences media  entertainment medical malpractice mergers  acquisitions native american new jersey new york pennsylvania private equity product liability project finance public policy real estate retail  e commerce securities sports tax technology telecommunications texas transportation trials white collar register already have access email password forgot your password remember login sign in aisling capital raises  million for third fund  pe hub subscribe to pe hub wire join over  of your peers get the mustread email for pevc professionals delivered to your inbox daily — for free us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions subscribe yes no registersign in a community for professionals in private capital aisling capital raises  million for third fund january   by pehub administrator aisling capital has closed its third fund with  million in capital commitments the new yorkbased venture firm focuses on the life sciences and healthcare sectors it had raised  million for its second fund in    press release aisling capital announced today that it raised us million in committed capital for its newest life sciences fund aisling capital iii lp aisling capital will invest its third fund primarily in companies developing pharmaceutical biopharmaceutical and medical products as well as in businesses that provide drug development manufacturing and other important services to the healthcare industry with a total of over us billion in committed capital under management the aisling capital team will also continue to manage the perseussoros biopharmaceutical fund lp and aisling capital ii lp   “we appreciate the support of our existing and new limited partners particularly during these times of market turbulence” commented dennis purcell senior managing partner of aisling capital mr purcell added “we believe the next several years will be a critical period for the life sciences industry in which multiple forces will converge to create opportunities for the prepared investor”   the aisling capital team is comprised of individuals with a combination of clinical transactional operational and capital markets expertise complemented by extensive networks in the life sciences industry the team is led by managing partners dennis purcell steve elms and andrew schiff md and newly promoted partners dov goldstein md anthony sun md and brett zbar md additionally josh bilenker md has been promoted to principal   about aisling capital   aisling capital is a dedicated life sciences private equity firm with over us billion under management headquartered in new york aisling capital invests in both private and public companies utilizing a wide variety of investment structures the aisling capital team’s combination of clinical operational and financial experience allows the firm to identify execute and realize investments across the life sciences industry   web site httpwwwaislingcapitalcom   dont miss out meet new and diverse managers in private equity venture capital and real estate at the third emerging manager connect east at new york citys harvard club click here for details sign up to our newsletter receive updates from our pe hub wire and top stories of the week newsletters first name last name email address us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions you are now subscribed to the pehub wire and top stories of the week newsletters buyouts insiderargosy group llc produces several free newsletters that are sent directly to the email you provide at registration namely pe hub wire pe hub canada wire pe hub wire top story of the week buyouts daily and vcj alert to enable us to keep providing these services free of charge we reserve the right to contact you with special invitations to sample or purchase private equityrelated products by submitting this free subscription request for any of these products you are also consenting to this communication should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email this will discontinue both the special invitations mentioned previously as well as your subscription to the weekly newsletter the information you provide will be safeguarded by argosy group llcbuyouts insider the company’s subsidiaries may use it to keep you informed of relevant products and services we occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you as an international group we may transfer your data on a global basis for the purposes indicated above we will never share your email or contact details with any outside company however should you have any questions please do not hesitate to contact us email protected top posts new oil and gas company native racks up  mln by iris dorbian bain capital double impact funds two companies by iris dorbian midocean to sell water pik for  bln by luisa beltran carlyle to invest in zerochaos by luisa beltran the pe hub podcast episode two by staff report awake security nabs over  mln from greylock and bain capital ventures by iris dorbian thoma bravo to sell sparta systems to new mountain by iris dorbian kkr to buy nature’s bounty from carlyle by luisa beltran microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft ld products  coupon code and up to  off printer ink  ld products we detected that your javascript seem to be disabled you must have javascript enabled in your browser to utilize the functionality of this website tax season sale  off ink and toner shop now quick reorder track order government my printers help  create account or sign in free shipping on all orders over † lifetime  satisfaction guarantee free shipping on orders over † low flat rate shipping  only  on orders under † multiple fulfillment centers  so you get your order faster orders placed before pm usually ship the same day †applies to orders delivered to the contiguous us close learn more reliability for a lifetime  all of our ld brand compatible ink and toner cartridges are backed by a lifetime guarantee verified excellence  our cartridges have been tested for performance quality and page yield so you know you are getting the absolute best product available your happiness matters  in the event that you are dissatisfied with your purchase simply let us know  well do our best to make it right close learn more special offers  items ink  toner office supplies paper cleaning  breakroom technology office furniture featured ink  toner brands all categories hp canon epson brother lexmark dell xerox samsung more ink  toner brands konica pitney bowes kyocera ricoh kodak sharp okidata toshiba panasonic refill kits featured office supply categories all categories writing  correction general supplies binders  accessories filing supplies envelopes  forms calendars  planners boards  easels desk organizers more office supply categories bags  travel accessories mailing  shipping storage  organizers tools  equipment cash handling labeling  labeling systems teaching  art featured paper categories all categories copy  multiuse paper notebooks pads  filler paper adhesive note pads photo paper brochure  specialty paper cards  stationary colored paper wide format paper featured cleaning  breakroom categories all categories cleaning supplies cleaning equipment breakroom supplies healthcare supplies safety  security facility supplies climate control featured technology categories all categories printers office machines  electronics power  backup network  cables d printing peripherals  memory drives  media shredders  accessories more technology categories audio video players computer accessories radio  mobile technology software  utilities cameras  scanners ink refill kits telephone  communication multimedia players displays  digital projectors featured office furnitures categories all categories furniture collections desks  tables chairs chair mats  accessories office decor  lighting armoires  bookcases filing storage  accessories carts  stands furniture accessories panel systems  accessories menu call reorder cart ink  toner office supplies hp canon epson brother lexmark dell xerox samsung okidata konica shop all printer brands office supplies paper cleaning technology office furniture ink  toner office supplies paper cleaning  breakroom technology office furniture my printers sign in track your order create account help special offers back general office supplies ink  toner hp canon epson brother lexmark dell xerox samsung okidata konica shop all printer brands  off ink  toner plus free shipping on all orders over  coupon code ldp applied expires  excludes oem items applies to orders delivered to the contiguous us scroll down for details find printer supplies fast easy  hassle free ink  toner finder select a printer brand select a printer brand top brands brother canon epson hewlett packard hp lexmark xerox all brands az acom amt amano astrojet birmy graphics brother bryce canon casio compaq computer language res copystar dec dataproducts dell dymo eicon laser electronic forms epson gestetner hasler hewlett packard hp ibm infoprint imagen imagistics interface systems kodak konicaminolta kyoceramita lanier lasermaster lexmark mimaki muratec mutoh nec nashuatec neopost newgen north atlantic oce okidata olivetti olympia panasonic pitney bowes primera printronix rena ricoh riso risograph roland samsung savin secap sharp sindoh star micronics tallygenicom tandem telenorma tenofax texas instruments toshiba xerox brother canon epson hewlett packard hp lexmark xerox acom amt amano astrojet birmy graphics brother bryce canon casio compaq computer language res copystar dec dataproducts dell dymo eicon laser electronic forms epson gestetner hasler hewlett packard hp ibm infoprint imagen imagistics interface systems kodak konicaminolta kyoceramita lanier lasermaster lexmark mimaki muratec mutoh nec nashuatec neopost newgen north atlantic oce okidata olivetti olympia panasonic pitney bowes primera printronix rena ricoh riso risograph roland samsung savin secap sharp sindoh star micronics tallygenicom tandem telenorma tenofax texas instruments toshiba xerox select a printerfamily select a printer family select a printer model select a printer model submit shop ink  toner from these top printer brands shop by printer brand hp hp officejet pro  hp officejet pro  hp envy  shop hp ink canon canon pixma mx canon pixma mg canon pixma mg shop canon ink epson epson workforce wf epson workforce wf epson workforce wf shop epson ink brother brother mfcjdw brother mfcjdw brother mfcjdw shop brother ink lexmark lexmark x lexmark prospect pro lexmark pro shop lexmark ink dell dell vw dell hcdw dell cw color shop dell ink xerox xerox phaser  xerox workcentre  xerox workcentre  shop xerox ink samsung samsung xpress cw samsung xpress mfw samsung xpress cfw shop samsung ink konicaminolta konica bizhub ce konica bizhub ce konica pagepro mf shop konica ink okidata okidata microline  turbo okidata mbw okidata oki mcw shop okidata ink shop all printer brands adding to cart added to cart add to get free shipping your order qualifies for free shipping price qty subtotal free shipping on orders over  to the contiguous us orders placed before pm pst typically ship the same day cart summary edit cart items in cart estimated shipping contiguous us ships same day coupon will be applied in shopping cart view cart continue shopping customers also bought other social login facebook sign in google sign in linkedin sign in quick reorder login  ld products we detected that your javascript seem to be disabled you must have javascript enabled in your browser to utilize the functionality of this website tax season sale  off ink and toner shop now quick reorder track order government my printers help  create account or sign in free shipping on all orders over † lifetime  satisfaction guarantee free shipping on orders over † low flat rate shipping  only  on orders under † multiple fulfillment centers  so you get your order faster orders placed before pm usually ship the same day †applies to orders delivered to the contiguous us close learn more reliability for a lifetime  all of our ld brand compatible ink and toner cartridges are backed by a lifetime guarantee verified excellence  our cartridges have been tested for performance quality and page yield so you know you are getting the absolute best product available your happiness matters  in the event that you are dissatisfied with your purchase simply let us know  well do our best to make it right close learn more special offers  items ink  toner office supplies paper cleaning  breakroom technology office furniture featured ink  toner brands all categories hp canon epson brother lexmark dell xerox samsung more ink  toner brands konica pitney bowes kyocera ricoh kodak sharp okidata toshiba panasonic refill kits featured office supply categories all categories writing  correction general supplies binders  accessories filing supplies envelopes  forms calendars  planners boards  easels desk organizers more office supply categories bags  travel accessories mailing  shipping storage  organizers tools  equipment cash handling labeling  labeling systems teaching  art featured paper categories all categories copy  multiuse paper notebooks pads  filler paper adhesive note pads photo paper brochure  specialty paper cards  stationary colored paper wide format paper featured cleaning  breakroom categories all categories cleaning supplies cleaning equipment breakroom supplies healthcare supplies safety  security facility supplies climate control featured technology categories all categories printers office machines  electronics power  backup network  cables d printing peripherals  memory drives  media shredders  accessories more technology categories audio video players computer accessories radio  mobile technology software  utilities cameras  scanners ink refill kits telephone  communication multimedia players displays  digital projectors featured office furnitures categories all categories furniture collections desks  tables chairs chair mats  accessories office decor  lighting armoires  bookcases filing storage  accessories carts  stands furniture accessories panel systems  accessories menu call reorder cart ink  toner office supplies hp canon epson brother lexmark dell xerox samsung okidata konica shop all printer brands office supplies paper cleaning technology office furniture ink  toner office supplies paper cleaning  breakroom technology office furniture my printers sign in track your order create account help special offers back general office supplies ink  toner hp canon epson brother lexmark dell xerox samsung okidata konica shop all printer brands adding to cart added to cart add to get free shipping your order qualifies for free shipping price qty subtotal free shipping on orders over  to the contiguous us orders placed before pm pst typically ship the same day cart summary edit cart items in cart estimated shipping contiguous us ships same day coupon will be applied in shopping cart view cart continue shopping customers also bought other social login facebook sign in google sign in linkedin sign in ld products  coupon code and up to  off printer ink  ld products we detected that your javascript seem to be disabled you must have javascript enabled in your browser to utilize the functionality of this website tax season sale  off ink and toner shop now quick reorder track order government my printers help  create account or sign in free shipping on all orders over † lifetime  satisfaction guarantee free shipping on orders over † low flat rate shipping  only  on orders under † multiple fulfillment centers  so you get your order faster orders placed before pm usually ship the same day †applies to orders delivered to the contiguous us close learn more reliability for a lifetime  all of our ld brand compatible ink and toner cartridges are backed by a lifetime guarantee verified excellence  our cartridges have been tested for performance quality and page yield so you know you are getting the absolute best product available your happiness matters  in the event that you are dissatisfied with your purchase simply let us know  well do our best to make it right close learn more special offers  items ink  toner office supplies paper cleaning  breakroom technology office furniture featured ink  toner brands all categories hp canon epson brother lexmark dell xerox samsung more ink  toner brands konica pitney bowes kyocera ricoh kodak sharp okidata toshiba panasonic refill kits featured office supply categories all categories writing  correction general supplies binders  accessories filing supplies envelopes  forms calendars  planners boards  easels desk organizers more office supply categories bags  travel accessories mailing  shipping storage  organizers tools  equipment cash handling labeling  labeling systems teaching  art featured paper categories all categories copy  multiuse paper notebooks pads  filler paper adhesive note pads photo paper brochure  specialty paper cards  stationary colored paper wide format paper featured cleaning  breakroom categories all categories cleaning supplies cleaning equipment breakroom supplies healthcare supplies safety  security facility supplies climate control featured technology categories all categories printers office machines  electronics power  backup network  cables d printing peripherals  memory drives  media shredders  accessories more technology categories audio video players computer accessories radio  mobile technology software  utilities cameras  scanners ink refill kits telephone  communication multimedia players displays  digital projectors featured office furnitures categories all categories furniture collections desks  tables chairs chair mats  accessories office decor  lighting armoires  bookcases filing storage  accessories carts  stands furniture accessories panel systems  accessories menu call reorder cart ink  toner office supplies hp canon epson brother lexmark dell xerox samsung okidata konica shop all printer brands office supplies paper cleaning technology office furniture ink  toner office supplies paper cleaning  breakroom technology office furniture my printers sign in track your order create account help special offers back general office supplies ink  toner hp canon epson brother lexmark dell xerox samsung okidata konica shop all printer brands  off ink  toner plus free shipping on all orders over  coupon code ldp applied expires  excludes oem items applies to orders delivered to the contiguous us scroll down for details find printer supplies fast easy  hassle free ink  toner finder select a printer brand select a printer brand top brands brother canon epson hewlett packard hp lexmark xerox all brands az acom amt amano astrojet birmy graphics brother bryce canon casio compaq computer language res copystar dec dataproducts dell dymo eicon laser electronic forms epson gestetner hasler hewlett packard hp ibm infoprint imagen imagistics interface systems kodak konicaminolta kyoceramita lanier lasermaster lexmark mimaki muratec mutoh nec nashuatec neopost newgen north atlantic oce okidata olivetti olympia panasonic pitney bowes primera printronix rena ricoh riso risograph roland samsung savin secap sharp sindoh star micronics tallygenicom tandem telenorma tenofax texas instruments toshiba xerox brother canon epson hewlett packard hp lexmark xerox acom amt amano astrojet birmy graphics brother bryce canon casio compaq computer language res copystar dec dataproducts dell dymo eicon laser electronic forms epson gestetner hasler hewlett packard hp ibm infoprint imagen imagistics interface systems kodak konicaminolta kyoceramita lanier lasermaster lexmark mimaki muratec mutoh nec nashuatec neopost newgen north atlantic oce okidata olivetti olympia panasonic pitney bowes primera printronix rena ricoh riso risograph roland samsung savin secap sharp sindoh star micronics tallygenicom tandem telenorma tenofax texas instruments toshiba xerox select a printerfamily select a printer family select a printer model select a printer model submit shop ink  toner from these top printer brands shop by printer brand hp hp officejet pro  hp officejet pro  hp envy  shop hp ink canon canon pixma mx canon pixma mg canon pixma mg shop canon ink epson epson workforce wf epson workforce wf epson workforce wf shop epson ink brother brother mfcjdw brother mfcjdw brother mfcjdw shop brother ink lexmark lexmark x lexmark prospect pro lexmark pro shop lexmark ink dell dell vw dell hcdw dell cw color shop dell ink xerox xerox phaser  xerox workcentre  xerox workcentre  shop xerox ink samsung samsung xpress cw samsung xpress mfw samsung xpress cfw shop samsung ink konicaminolta konica bizhub ce konica bizhub ce konica pagepro mf shop konica ink okidata okidata microline  turbo okidata mbw okidata oki mcw shop okidata ink shop all printer brands adding to cart added to cart add to get free shipping your order qualifies for free shipping price qty subtotal free shipping on orders over  to the contiguous us orders placed before pm pst typically ship the same day cart summary edit cart items in cart estimated shipping contiguous us ships same day coupon will be applied in shopping cart view cart continue shopping customers also bought other social login facebook sign in google sign in linkedin sign in